



CP/1642

UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of)
Ming-Fong Lin et al.)
Serial No.: 09/919,196)
Filed: July 31, 2001)
For: "NOVEL PROSTATE CANCER)
CELL LINES")

Examiner: DAVIS, Minh Tam B

Art Unit: 1642

Response to Paper No. 5

RECEIVED

NOV 07 2002

TECH CENTER 1600/2300

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited on 10-29-02 with the United States Postal Service as first class mail in an envelope properly addressed to COMMISSIONER OF PATENTS AND TRADEMARKS, Washington, D.C. 20231.

10-29-02
Date

Janice Nightlinger
Janice Nightlinger

**TRAVERSAL AND REQUEST FOR
RECONSIDERATION OF REQUIREMENT FOR RESTRICTION**

A restriction requirement under 35 U.S.C. §121 was set forth in the Official Action dated October 1, 2002 in the above-identified patent application. It is the Examiner's position that claims 1-11 in the present application are drawn to six (6) patentably distinct invention which are as follows:

Group I, claims 1-4, drawn to a human prostate cancer-associated neuroendocrine (NE)-like cell line.

Group II, claim 5, drawn to a method of obtaining a NE-like cell line from prostate cells.